Marine omega-3 polyunsaturated fatty acids induce sex-specific changes in reinforcer-controlled behaviour and neurotransmitter metabolism in a spontaneously hypertensive rat model of ADHD

Behavioral and Brain Functions

Volumn 8, Issue , 2012, Pages

  Dervola, Kine S ^a   Roberg, Bjørg T ^a   Wøien, Grete ^a   Bogen, Inger Lise ^a   Sandvik, Torbjørn H ^b   Sagvolden, Terje ^a   Drevon, Christian A ^a   Johansen, Espen Borgå ^c   Walaas, Sven Ivar ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO METROPOLITAN UNIVERSITY   (Norway)

Author keywords

ADHD; Behaviour; Dopamine; Glutamate; Neostriatum; Omega 3; Serotonin

Indexed keywords

AMINO ACID; GLUTAMIC ACID; GLYCINE; MONOAMINE; NEUROTRANSMITTER; OMEGA 3 FATTY ACID; SEROTONIN; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION DEFICIT DISORDER; CATABOLISM; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMPULSIVENESS; LOCOMOTION; MALE; NEUROTRANSMITTER UPTAKE; NONHUMAN; POSTNATAL GROWTH; PREGNANCY; PRIORITY JOURNAL; PROGENY; RAT; REINFORCEMENT; SEX DIFFERENCE; SPONTANEOUSLY HYPERTENSIVE RAT; VITAMIN SUPPLEMENTATION; ANIMAL; DIET THERAPY; DISEASE MODEL; HUMAN; HYPERTENSION; METABOLISM; NEWBORN; SEXUAL DEVELOPMENT; WISTAR KYOTO RAT;

ANIMALS; ANIMALS, NEWBORN; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DISEASE MODELS, ANIMAL; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; HYPERTENSION; MALE; NEUROTRANSMITTER AGENTS; PREGNANCY; RATS; RATS, INBRED SHR; RATS, INBRED WKY; REINFORCEMENT (PSYCHOLOGY); SEX CHARACTERISTICS;

EID: 84873654102     PISSN: None     EISSN: 17449081     Source Type: Journal    
DOI: 10.1186/1744-9081-8-56     Document Type: Article

References (84)

1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007, 164:942-948. 10.1176/appi.ajp.164.6.942, 17541055.
2. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2000, Washington DC: American Psychiatric Association, 4, text revision edn, American Psychiatric Association.
3. Sagvolden T, Johansen EB, Aase H, Russell VA. A dynamic developmental theory of attention-deficit/hyperactivity disorder (ADHD) predominantly hyperactive/impulsive and combined subtypes. Behav Brain Sci 2005, 28:397-419.
4. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005, 57:1313-1323. 10.1016/j.biopsych.2004.11.024, 15950004.
5. Caspi A, Moffitt TE. Gene-environment interactions in psychiatry: joining forces with neuroscience. Nat Rev Neurosci 2006, 7:583-590.
6. Willcutt EG, Pennington BF, Olson RK, DeFries JC. Understanding comorbidity: a twin study of reading disability and attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2007, 144B:709-714. 10.1002/ajmg.b.30310, 17440942.
7. McNamara RK, Carlson SE. Role of omega-3 fatty acids in brain development and function: potential implications for the pathogenesis and prevention of psychopathology. Prostaglandins Leukot Essent Fatty Acids 2006, 75:329-349. 10.1016/j.plefa.2006.07.010, 16949263.
8. Cole GM, Ma QL, Frautschy SA. Omega-3 fatty acids and dementia. Prostaglandins Leukot Essent Fatty Acids 2009, 81:213-221. 10.1016/j.plefa.2009.05.015, 19523795.
9. Cao D, Kevala K, Kim J, Moon HS, Jun SB, Lovinger D, et al. Docosahexaenoic acid promotes hippocampal neuronal development and synaptic function. J Neurochem 2009, 111:510-521. 10.1111/j.1471-4159.2009.06335.x, 2773444, 19682204.
10. Pawlosky RJ, Hibbeln JR, Novotny JA, Salem N. Physiological compartmental analysis of alpha-linolenic acid metabolism in adult humans. J Lipid Res 2001, 42:1257-1265.
11. Burdge GC, Wootton SA. Conversion of alpha-linolenic acid to eicosapentaenoic, docosapentaenoic and docosahexaenoic acids in young women. Br J Nutr 2002, 88:411-420. 10.1079/BJN2002689, 12323090.
12. Burdge GC, Jones AE, Wootton SA. Eicosapentaenoic and docosapentaenoic acids are the principal products of alpha-linolenic acid metabolism in young men*. Br J Nutr 2002, 88:355-363. 10.1079/BJN2002662, 12323085.
13. Drevon CA. Marine oils and their effects. Nutr Rev 1992, 50:38-45.
14. Birch EE, Garfield S, Hoffman DR, Uauy R, Birch DG. A randomized controlled trial of early dietary supply of long-chain polyunsaturated fatty acids and mental development in term infants. Dev Med Child Neurol 2000, 42:174-181. 10.1017/S0012162200000311, 10755457.
15. Helland IB, Smith L, Saarem K, Saugstad OD, Drevon CA. Maternal supplementation with very-long-chain n-3 fatty acids during pregnancy and lactation augments children's IQ at 4 years of age. Pediatrics 2003, 111:e39-e44. 10.1542/peds.111.1.e39, 12509593.
16. Helland IB, Smith L, Blomen B, Saarem K, Saugstad OD, Drevon CA. Effect of supplementing pregnant and lactating mothers with n-3 very-long-chain fatty acids on children's IQ and body mass index at 7 years of age. Pediatrics 2008, 122:e472-e479. 10.1542/peds.2007-2762, 18676533.
17. Henriksen C, Haugholt K, Lindgren M, Aurvag AK, Ronnestad A, Gronn M, et al. Improved cognitive development among preterm infants attributable to early supplementation of human milk with docosahexaenoic acid and arachidonic acid. Pediatrics 2008, 121:1137-1145. 10.1542/peds.2007-1511, 18519483.
18. Willatts P, Forsyth JS, DiModugno MK, Varma S, Colvin M. Influence of long-chain polyunsaturated fatty acids on infant cognitive function. Lipids 1998, 33:973-980. 10.1007/s11745-998-0294-7, 9832076.
19. Bloch MH, Qawasmi A. Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry 2011, 50:991-1000. 10.1016/j.jaac.2011.06.008, 21961774.
20. Millichap JG, Yee MM. The diet factor in attention-deficit/hyperactivity disorder. Pediatrics 2012, 129:330-337. 10.1542/peds.2011-2199, 22232312.
21. Antalis CJ, Stevens LJ, Campbell M, Pazdro R, Ericson K, Burgess JR. Omega-3 fatty acid status in attention-deficit/hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids 2006, 75:299-308. 10.1016/j.plefa.2006.07.004, 16962757.
22. Dopheide JA, Pliszka SR. Attention-deficit-hyperactivity disorder: an update. Pharmacotherapy 2009, 29:656-679. 10.1592/phco.29.6.656, 19476419.
23. Peet M, Stokes C. Omega-3 fatty acids in the treatment of psychiatric disorders. Drugs 2005, 65:1051-1059. 10.2165/00003495-200565080-00002, 15907142.
24. Kim HY, Moon HS, Cao D, Lee J, Kevala K, Jun SB, et al. N-Docosahexaenoylethanolamide promotes development of hippocampal neurons. Biochem J 2011, 435:327-336. 10.1042/BJ20102118, 3169088, 21281269.
25. Su HM. Mechanisms of n-3 fatty acid-mediated development and maintenance of learning memory performance. J Nutr Biochem 2010, 21:364-373. 10.1016/j.jnutbio.2009.11.003, 20233652.
26. Levant B, Ozias MK, Carlson SE. Sex-specific effects of brain LC-PUFA composition on locomotor activity in rats. Physiol Behav 2006, 89:196-204. 10.1016/j.physbeh.2006.06.007, 16875705.
27. Chalon S, Vancassel S, Zimmer L, Guilloteau D, Durand G. Polyunsaturated fatty acids and cerebral function: focus on monoaminergic neurotransmission. Lipids 2001, 36:937-944. 10.1007/s11745-001-0804-7, 11724466.
28. Aghajanian GK, Rosecrans JA, Sheard MH. Serotonin: release in the forebrain by stimulation of midbrain raphe. Science 1967, 156:402-403. 10.1126/science.156.3773.402, 4886538.
29. Tripp G, Wickens J. Reinforcement 2012, Neurotherapeutics: Dopamine and Rodent Models in Drug Development for ADHD.
30. Kebir O, Joober R. Neuropsychological endophenotypes in attention-deficit/hyperactivity disorder: a review of genetic association studies. Eur Arch Psychiatry Clin Neurosci 2011, 261:583-594. 10.1007/s00406-011-0207-5, 21409419.
31. Arnsten AF, Pliszka SR. Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders. Pharmacol Biochem Behav 2011, 99:211-216. 10.1016/j.pbb.2011.01.020, 3129015, 21295057.
32. Russell VA. Dopamine hypofunction possibly results from a defect in glutamate-stimulated release of dopamine in the nucleus accumbens shell of a rat model for attention deficit hyperactivity disorder-the spontaneously hypertensive rat. Neurosci Biobehav Rev 2003, 27:671-682. 10.1016/j.neubiorev.2003.08.010, 14624811.
33. Gainetdinov RR, Mohn AR, Bohn LM, Caron MG. Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter. Proc Natl Acad Sci U S A 2001, 98:11047-11054. 10.1073/pnas.191353298, 58681, 11572967.
34. Gainetdinov RR. Strengths and limitations of genetic models of ADHD. Atten Defic Hyperact Disord 2010, 2:21-30. 10.1007/s12402-010-0021-3, 21432587.
35. Sagvolden T. Behavioral validation of the spontaneously hypertensive rat (SHR) as an animal model of attention-deficit/hyperactivity disorder (AD/HD). Neurosci Biobehav Rev 2000, 24:31-39. 10.1016/S0149-7634(99)00058-5, 10654658.
36. Sagvolden T, Russell VA, Aase H, Johansen EB, Farshbaf M. Rodent models of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005, 57:1239-1247. 10.1016/j.biopsych.2005.02.002, 15949994.
37. Sagvolden T, Johansen EB, Woien G, Walaas SI, Storm-Mathisen J, Bergersen LH, et al. The spontaneously hypertensive rat model of ADHD-the importance of selecting the appropriate reference strain. Neuropharmacology 2009, 57:619-626. 10.1016/j.neuropharm.2009.08.004, 2783904, 19698722.
38. Chalon S. Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins Leukot Essent Fatty Acids 2006, 75:259-269. 10.1016/j.plefa.2006.07.005, 16963244.
39. Sagvolden T, Xu T. l-Amphetamine improves poor sustained attention while d-amphetamine reduces overactivity and impulsiveness as well as improves sustained attention in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD). Behav Brain Funct 2008, 4:3. 10.1186/1744-9081-4-3, 2265273, 18215285.
40. Rokling-Andersen MH, Rustan AC, Wensaas AJ, Kaalhus O, Wergedahl H, Rost TH, et al. Marine n-3 fatty acids promote size reduction of visceral adipose depots, without altering body weight and composition, in male Wistar rats fed a high-fat diet. Br J Nutr 2009, 102:995-1006. 10.1017/S0007114509353210, 19397836.
41. Johansen EB, Knoff M, Fonnum F, Lausund PL, Walaas SI, Woien G, et al. Postnatal exposure to PCB 153 and PCB 180, but not to PCB 52, produces changes in activity level and stimulus control in outbred male Wistar Kyoto rats. Behav Brain Funct 2011, 7:18. 10.1186/1744-9081-7-18, 3126714, 21615898.
42. Jensenius AR, Godøy RI, Wanderley MM. Developing Tools for Studying Musical Gestures within the (Max/MSP/Jitter) Environment, 282-285. Proceedings of the International Computer Music Conference 2005, 4-10. Barcelona.
43. Myers JL, Well AD. Research design and statistical analysis 2003, Mahwah, NJ: Lawrence Erlbaum Associates.
44. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985, 150:76-85. 10.1016/0003-2697(85)90442-7, 3843705.
45. Hassel B, Bachelard H, Jones P, Fonnum F, Sonnewald U. Trafficking of amino acids between neurons and glia in vivo. Effects of inhibition of glial metabolism by fluoroacetate. J Cereb Blood Flow Metab 1997, 17:1230-1238.
46. Hallman H, Jonsson G. Neurochemical studies on central dopamine neurons-regional characterization of dopamine turnover. Med Biol 1984, 62:198-209.
47. Jones MW, Kilpatrick IC, Phillipson OT. The agranular insular cortex: a site of unusually high dopamine utilisation. Neurosci Lett 1986, 72:330-334. 10.1016/0304-3940(86)90536-7, 3822236.
48. Bustillo JR, Rowland LM, Mullins P, Jung R, Chen H, Qualls C, et al. 1H-MRS at 4 tesla in minimally treated early schizophrenia. Mol Psychiatry 2010, 15:629-636. 10.1038/mp.2009.121, 2892215, 19918243.
49. Ongur D, Haddad S, Prescot AP, Jensen JE, Siburian R, Cohen BM, et al. Relationship between genetic variation in the glutaminase gene GLS1 and brain glutamine/glutamate ratio measured in vivo. Biol Psychiatry 2011, 70:169-174. 10.1016/j.biopsych.2011.01.033, 3125415, 21457947.
50. Johnson JW, Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 1987, 325:529-531. 10.1038/325529a0, 2433595.
51. Kleckner NW, Dingledine R. Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science 1988, 241:835-837. 10.1126/science.2841759, 2841759.
52. Ericson M, Molander A, Stomberg R, Soderpalm B. Taurine elevates dopamine levels in the rat nucleus accumbens; antagonism by strychnine. Eur J Neurosci 2006, 23:3225-3229. 10.1111/j.1460-9568.2006.04868.x, 16820013.
53. Iversen LL, Iversen SD, Bloom FE, Roth RH. Introduction to neuropsychopharmacology 2009, New York: Oxford University Press, Inc.
54. Cao D, Xue R, Xu J, Liu Z. Effects of docosahexaenoic acid on the survival and neurite outgrowth of rat cortical neurons in primary cultures. J Nutr Biochem 2005, 16:538-546. 10.1016/j.jnutbio.2005.02.002, 16115542.
55. Kuperstein F, Eilam R, Yavin E. Altered expression of key dopaminergic regulatory proteins in the postnatal brain following perinatal n-3 fatty acid dietary deficiency. J Neurochem 2008, 106:662-671. 10.1111/j.1471-4159.2008.05418.x, 18410511.
56. Walaas SI, Hemmings HC, Greengard P, Nairn AC. Beyond the dopamine receptor: regulation and roles of serine/threonine protein phosphatases. Front Neuroanat 2011, 5:50. 3162284, 21904525.
57. Waelti P, Dickinson A, Schultz W. Dopamine responses comply with basic assumptions of formal learning theory. Nature 2001, 412:43-48. 10.1038/35083500, 11452299.
58. Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol 1998, 80:1-27.
59. Pan WX, Schmidt R, Wickens JR, Hyland BI. Dopamine cells respond to predicted events during classical conditioning: evidence for eligibility traces in the reward-learning network. J Neurosci 2005, 25:6235-6242. 10.1523/JNEUROSCI.1478-05.2005, 15987953.
60. Yung KK, Smith AD, Levey AI, Bolam JP. Synaptic connections between spiny neurons of the direct and indirect pathways in the neostriatum of the rat: evidence from dopamine receptor and neuropeptide immunostaining. Eur J Neurosci 1996, 8:861-869. 10.1111/j.1460-9568.1996.tb01573.x, 8743734.
61. Fienberg AA, Hiroi N, Mermelstein PG, Song W, Snyder GL, Nishi A, et al. DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science 1998, 281:838-842.
62. Rodrigues TB, Granado N, Ortiz O, Cerdan S, Moratalla R. Metabolic interactions between glutamatergic and dopaminergic neurotransmitter systems are mediated through D(1) dopamine receptors. J Neurosci Res 2007, 85:3284-3293. 10.1002/jnr.21302, 17455302.
63. Goldstein M, Lieberman A. The role of the regulatory enzymes of catecholamine synthesis in Parkinson's disease. Neurology 1992, 42:8-12.
64. McNamara RK, Able J, Liu Y, Jandacek R, Rider T, Tso P, et al. Omega-3 fatty acid deficiency during perinatal development increases serotonin turnover in the prefrontal cortex and decreases midbrain tryptophan hydroxylase-2 expression in adult female rats: dissociation from estrogenic effects. J Psychiatr Res 2009, 43:656-663. 10.1016/j.jpsychires.2008.09.011, 2679262, 18986658.
65. Simchon Y, Weizman A, Rehavi M. The effect of chronic methylphenidate administration on presynaptic dopaminergic parameters in a rat model for ADHD. Eur Neuropsychopharmacol 2010, 20:714-720. 10.1016/j.euroneuro.2010.04.007, 20493667.
66. Oades RD, Lasky-Su J, Christiansen H, Faraone SV, Sonuga-Barke EJ, Banaschewski T, et al. The influence of serotonin- and other genes on impulsive behavioral aggression and cognitive impulsivity in children with attention-deficit/hyperactivity disorder (ADHD): Findings from a family-based association test (FBAT) analysis. Behav Brain Funct 2008, 4:48. 10.1186/1744-9081-4-48, 2577091, 18937842.
67. Darstein M, Loschmann PA, Knorle R, Feuerstein TJ. Strychnine-sensitive glycine receptors inducing [3H]-acetylcholine release in rat caudatoputamen: a new site of action of ethanol?. Naunyn Schmiedebergs Arch Pharmacol 1997, 356:738-745. 10.1007/PL00005112, 9453458.
68. Molander A, Soderpalm B. Glycine receptors regulate dopamine release in the rat nucleus accumbens. Alcohol Clin Exp Res 2005, 29:17-26. 10.1097/01.ALC.0000150006.17168.F7, 15654287.
69. Sergeeva OA, Haas HL. Expression and function of glycine receptors in striatal cholinergic interneurons from rat and mouse. Neuroscience 2001, 104:1043-1055. 10.1016/S0306-4522(01)00130-0, 11457589.
70. Hamill TG, Eng W, Jennings A, Lewis R, Thomas S, Wood S, et al. The synthesis and preclinical evaluation in rhesus monkey of [(1)F]MK-6577 and [(1)(1)C]CMPyPB glycine transporter 1 positron emission tomography radiotracers. Synapse 2011, 65:261-270. 10.1002/syn.20842, 20687108.
71. Nagy K, Marko B, Zsilla G, Matyus P, Pallagi K, Szabo G, et al. Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone. Neurochem Res 2010, 35:2096-2106. 10.1007/s11064-010-0241-0, 20725779.
72. Perry KW, Falcone JF, Fell MJ, Ryder JW, Yu H, Love PL, et al. Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas. Neuropharmacology 2008, 55:743-754. 10.1016/j.neuropharm.2008.06.016, 18602930.
73. Vengeliene V, Leonardi-Essmann F, Sommer WH, Marston HM, Spanagel R. Glycine transporter-1 blockade leads to persistently reduced relapse-like alcohol drinking in rats. Biol Psychiatry 2010, 68:704-711. 10.1016/j.biopsych.2010.05.029, 20655511.
74. Kuriyama K, Ida S, Ohkuma S. Alteration of cerebral taurine biosynthesis in spontaneously hypertensive rats. J Neurochem 1984, 42:1600-1606. 10.1111/j.1471-4159.1984.tb12748.x, 6726227.
75. Breitinger HG, Becker CM. The inhibitory glycine receptor-simple views of a complicated channel. ChemBioChem 2002, 3:1042-1052. 10.1002/1439-7633(20021104)3:11<1042::AID-CBIC1042>3.0.CO;2-7, 12404628.
76. Haas HL, Hosli L. The depression of brain stem neurones by taurine and its interaction with strychnine and bicuculline. Brain Res 1973, 52:399-402.
77. Pan ZH, Slaughter MM. Comparison of the actions of glycine and related amino acids on isolated third order neurons from the tiger salamander retina. Neuroscience 1995, 64:153-164. 10.1016/0306-4522(94)00399-P, 7708201.
78. Hussy N, Deleuze C, Pantaloni A, Desarmenien MG, Moos F. Agonist action of taurine on glycine receptors in rat supraoptic magnocellular neurones: possible role in osmoregulation. J Physiol 1997, 502(Pt 3):609-621. 1159532, 9279812.
79. Greengard P. The neurobiology of slow synaptic transmission. Science 2001, 294:1024-1030. 10.1126/science.294.5544.1024, 11691979.
80. Andersen SL, Teicher MH. Sex differences in dopamine receptors and their relevance to ADHD. Neurosci Biobehav Rev 2000, 24:137-141. 10.1016/S0149-7634(99)00044-5, 10654670.
81. Gogos JA, Morgan M, Luine V, Santha M, Ogawa S, Pfaff D, et al. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci U S A 1998, 95:9991-9996. 10.1073/pnas.95.17.9991, 21449, 9707588.
82. Huotari M, Gogos JA, Karayiorgou M, Koponen O, Forsberg M, Raasmaja A, et al. Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice. Eur J Neurosci 2002, 15:246-256. 10.1046/j.0953-816x.2001.01856.x, 11849292.
83. Davis JF, Tracy AL, Schurdak JD, Tschop MH, Lipton JW, Clegg DJ, et al. Exposure to elevated levels of dietary fat attenuates psychostimulant reward and mesolimbic dopamine turnover in the rat. Behav Neurosci 2008, 122:1257-1263. 2597276, 19045945.
84. Schultz W. Multiple dopamine functions at different time courses. Annu Rev Neurosci 2007, 30:259-288. 10.1146/annurev.neuro.28.061604.135722, 17600522.